Veracyte (VCYT) Change in Accured Expenses (2012 - 2026)

Veracyte has reported Change in Accured Expenses for 15 years, with the latest figure at $6.6 million in Q2 2026.

• Change in Accured Expenses for Q2 2026 came in at $6.6 million, down 2.37% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.9 million (up 468.46% YoY), and the FY2025 annual result was $6.3 million, up 78.37% from the prior year.
• Change in Accured Expenses climbed to $6.6 million in Q2 2026, from -$6.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.9 million in Q2 2024 and troughed at -$9.0 million in Q1 2024.
• A 5-year average of $321000.0 and a median of -$165500.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest annual swing landed in 2023, when Change in Accured Expenses sank 1879.74%; it then soared 45525.0% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2022, then increased by 29.34% to $2.7 million in 2023, then slumped by 112.89% to -$351000.0 in 2024, then sank by 104.56% to -$718000.0 in 2025, then soared by 1024.37% to $6.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $6.6 million in Q2 2026, -$6.1 million in Q1 2026, and -$718000.0 in Q4 2025.